All conditions

Sjogren's Syndrome

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

65
Trials on record
16
Recruiting now
0
Australian sites
0
Phase 3 trials
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Sjogren's Syndrome →

Get alerts when Sjogren's Syndrome trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Sjögren's Syndrome

Sjögren's syndrome is a condition where the immune system mistakenly attacks the body's own moisture-producing glands, particularly those that make saliva and tears. This means the most common symptoms are a persistently dry mouth and dry eyes, though some people also experience fatigue, joint pain, or dryness in other parts of the body. It is an autoimmune condition, which means the body's defence system, which is normally meant to fight infections, starts targeting healthy tissue instead.

In Australia, Sjögren's syndrome is more common than many people realise. It is estimated to affect around one in every hundred Australians, making it one of the more prevalent autoimmune conditions in the country. It can occur on its own, which doctors sometimes call primary Sjögren's, or it can appear alongside another autoimmune condition such as rheumatoid arthritis or lupus, which is referred to as secondary Sjögren's. While it can affect people of any age or gender, it is diagnosed far more often in women, and most commonly in those over forty.

Because Sjögren's affects different people in different ways, care is usually tailored to the individual and managed by a team that may include a rheumatologist, eye specialist, and dentist. General approaches often focus on relieving symptoms and protecting the eyes and teeth from complications that dryness can cause over time. There are products and medications available that can help manage dryness and other symptoms. Regular check-ups are an important part of living with this condition, and speaking openly with your healthcare team about how your symptoms are affecting your daily life will help them provide the most appropriate support.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Sjogren's Syndrome in Australia right now? Here's what's publicly known.

  • No PBS-subsidised medicines are currently mapped for Sjogren's Syndrome on Voxsanity. Your doctor or pharmacist can advise on what may be available.
  • No trials currently recruiting at Australian sites right now. Worldwide trials may still be an option. See the trial list below.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

Research pipeline

Where trials for Sjogren's Syndrome currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Sjogren's Syndrome.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Sjogren's Syndrome by country. Australia is highlighted.

Showing the top 10 of 26 countries with trial sites.

Clinical trials for Sjogren's Syndrome

Showing 17 of 17 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT04035668 · Novartis Pharmaceuticals Phase 2 · 12 countries Terminated
Terminated Phase 2 Est. completion 23 November 2021
🇦🇺 AU🇧🇪 BE🇧🇬 BG🇨🇳 CN🇩🇰 DK🇩🇪 DE🇭🇺 HU🇪🇸 ES +4 more

**Who might be able to join this trial:** - You have been diagnosed with Sjögren's Syndrome (a condition that affects moisture-producing glands) based on the 2016 international diagnostic guidelines - Your Sjögren's Syndrome is active enough to score at least 5 points on a specific disease activity assessment used by d...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03047369 · Children's Hospital of Philadelphia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 December 2030
🇺🇸 US

**Who might be able to join this trial:** **For people who may have a white matter brain disorder:** - You can be male or female, and there is no age restriction - You have a suspected or confirmed diagnosis of a leukodystrophy (a disease affecting the white matter of the brain), based on a brain scan or an existing d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03509064 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 January 2027
🇫🇷 FR

**Who might be able to join this trial:** - You have been formally diagnosed with primary Sjögren's syndrome - You are over 18 years old - You have not received biologic medications or intravenous immunoglobulin therapy in the 6 months before the study starts *If joining the main study group (Arm 1):* - You have sympt...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03816345 · National Cancer Institute (NCI) Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 30 March 2028
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who have a confirmed cancer that has spread or cannot be removed by surgery, or who have a cancer type for which a PD-1/PD-L1 immunotherapy drug has been approved (including melanoma, non-small cell lung cancer, bladder cancer, kidney cancer, certain...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04806620 · Brain Inflammation Collaborative Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2030
🇺🇸 US

**Who might be able to join this trial:** - You have been told by a doctor — or believe yourself — that you have a condition linked to an infection, such as Long COVID, chronic Lyme disease, ME/CFS, or PANS/PANDAS - You have been told by a doctor — or believe yourself — that you have a nerve, immune system, or autonomi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05605314 · Peking University Third Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with dry eye disease (DED) based on internationally recognised guidelines (called TFOS DEWS II criteria) - If joining the Sjögren's syndrome group specifically, you have also been diagnosed with primary Sjögren's syndrome (an autoimmune condition that...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06875102 · Centre Hospitalier Universitaire de Saint Etienne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇫🇷 FR

**Who might be able to join this trial:** - You are over 18 years old - You are covered by a social security or health insurance scheme - You have been diagnosed with Sjögren's syndrome according to recognised medical criteria (ACR/EULAR 2016 or AECG 2002) - You have regular check-ups for your Sjögren's syndrome at lea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06947460 · Beijing GoBroad Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇨🇳 CN

Who might be able to join this trial: **For people with Refractory Lupus Nephritis (LN):** - People aged 10–65 of any gender whose lupus nephritis has not responded to at least one standard immune-suppressing treatment (such as steroids or cyclophosphamide) over 3–6 months, with protein in the urine not improving or w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06979531 · Immunovant Sciences GmbH Phase 2 · 16 countries Recruiting
Recruiting Phase 2 Est. completion 1 July 2028
🇦🇷 AR🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇴 CO🇩🇪 DE🇬🇷 GR🇭🇺 HU +8 more

Who might be able to join this trial: - You have been diagnosed with primary Sjögren's disease for at least 12 months before the screening visit, and your diagnosis meets the recognised 2016 international classification standards for the condition. - Your Sjögren's disease is considered moderately to severely active, b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06991114 · Artiva Biotherapeutics, Inc. Phase 2 · 11 countries Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇧🇷 BR🇧🇬 BG🇫🇷 FR🇩🇪 DE🇮🇹 IT🇵🇱 PL🇵🇹 PT🇷🇴 RO +3 more

**Who might be able to join this trial:** *For people with Rheumatoid Arthritis (RA):* - You have a confirmed diagnosis of rheumatoid arthritis based on recognised medical criteria. - Your blood tests show a positive result for Rheumatoid Factor (RF) or a related marker called ACPA. - Your blood tests show signs of in...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07041099 · Cullinan Therapeutics Inc. Phase 1 · 4 countries Recruiting
Recruiting Phase 1 Est. completion 15 March 2028
🇫🇷 FR🇩🇪 DE🇮🇹 IT🇺🇸 US

**Who might be able to join this trial:** - You must have been diagnosed with Sjögren's disease (SjD) at least 24 weeks before your first study visit, and meet the standard 2016 classification criteria for this condition. - Your Sjögren's disease must be moderately to severely active at the time of screening, based on...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07123519 · China Immunotech (Beijing) Biotechnology Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 13 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old (inclusive). - Your blood counts meet minimum levels — specifically, your infection-fighting white blood cells and red blood cells are above certain thresholds (confirm with trial site for exact values). - Your liver is functioning well en...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07153276 · University of Sao Paulo General Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 27 September 2029
🇧🇷 BR

Who might be able to join this trial: - You have been diagnosed with Sjögren's disease based on recognised international classification standards from 2016. - Your Sjögren's disease is currently stable and not very active, and you are either not taking steroid medications or taking no more than 15 mg per day of prednis...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07167537 · Beijing GoBroad Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old - You are generally able to carry out daily activities (your overall health and activity level meets a certain standard — confirm with trial site) - Your major organs (such as kidneys, liver, and heart) are working well enough to safely pa...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07184450 · Chongqing Precision Biotech Co., Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 5 years old or older. - You have been diagnosed with a treatment-resistant (refractory) B-cell-related childhood rheumatic disease, which may include juvenile dermatomyositis, polyarticular juvenile idiopathic arthritis, systemic sclerosis, or primary Sjögren's syndr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07249060 · Hospital Universitario Araba Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇪🇸 ES

**Who might be able to join this trial:** This trial has two separate groups (called "cohorts"). Please check which group may apply to you: **Group 1 – Cancer Immunotherapy Group (ICI cohort):** - You are about to start or have just started treatment with one or two immune checkpoint inhibitor (immunotherapy) drugs,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07277257 · Center For Sight Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older and have been diagnosed with dry eye disease caused by Sjögren's Syndrome within the last 2 years. - You have used or wanted to use artificial tears (eye drops for dryness) for your dry eye symptoms at some point in the last 2 months. - Your eyes...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Sjogren's Syndrome. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Two organisations support people with Sjogren's syndrome: the Australian Sjogren's Syndrome Association (TASSA), which is longer established, and Sjogren's Australia, which is newer.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.